Clinical Trial Update: A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Celltrion's Phase 3 trial evaluating subcutaneous CT-P13 for moderately to severely active rheumatoid arthritis has completed. The study assessed efficacy and s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CT-P13 (infliximab biosimilar)

Snippet

Sponsor: Celltrion | Conditions: Moderately to Severely Active Rheumatoid Arthritis | Phase 3 | Status: COMPLETED